Testing the role of apoA-I, HDL, and cholesterol efflux in the atheroprotective action of low-level apoE expression

Journal of Lipid Research

Volumn 44, Issue 12, 2003, Pages 2331-2338

  Thorngate, Fayanne E ^a   Yancey, Patricia G ^b   Kellner Weibel, Ginny ^b   Rudel, Lawrence L ^c   Rothblat, George H ^b   Williams, David L ^a  

^a STONY BROOK UNIVERSITY   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

ABCA1; Apolipoprotein A IV; Apolipoprotein E; Atherosclerosis; Cholesterol efflux; Cholesteryl ester

Indexed keywords

ABC TRANSPORTER; ABC TRANSPORTER A1; APOLIPOPROTEIN A1; APOLIPOPROTEIN E; CHOLESTEROL; CHOLESTEROL ESTER; HIGH DENSITY LIPOPROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL TRANSPORT; GENOTYPE; KNOCKOUT MOUSE; MACROPHAGE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; TRANSGENE; TRANSGENIC MOUSE;

ANIMALS; APOLIPOPROTEIN A-I; APOLIPOPROTEINS A; APOLIPOPROTEINS E; ARTERIOSCLEROSIS; ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL TRANSPORT; CHOLESTEROL; CROSSES, GENETIC; FEMALE; GENE DELETION; LIPOPROTEINS, HDL; MALE; MICE; MICE, TRANSGENIC;

EID: 0347724156     PISSN: 00222275     EISSN: None     Source Type: Journal    
DOI: 10.1194/jlr.M300224-JLR200     Document Type: Article

References (46)

1. Williams, K. J., and I. Tabas. 1995. The response-to-retention hypothesis of early atherogenesis. Arterioscler. Thromb. Vasc. Biol. 15: 551-561.
2. Thorngate, F. E., L. L. Rudel, R. L. Walzem, and D. L. Williams. 2000. Low levels of extrahepatic non-macrophage apoE inhibit atherosclerosis without correcting hypercholesterolemia in apoE-deficient mice. Arterioscler. Thromb. Vasc. Biol. 20: 1939-1945.
3. Zhu, Y., S. Bellosta, C. Langer, F. Bernini, R. E. Pitas, R. W. Mahley, G. Assmann, and A. von Eckardstein. 1998. Low-dose expression of a human apolipoprotein E transgene in macrophages restores cholesterol efflux capacity of apolipoprotein E-deficient mouse plasma. Proc. Natl. Acad. Sci. USA. 95: 7585-7590.
4. Hasty, A. H., L. MacRae, S. J. Brandt, V. R. Babaev, L. A. Gleaves, and S. Fazio. 1999. Retroviral gene therapy in ApoE-deficient mice Apo E expression in the artery wall reduces early foam cell lesion formation. Basic Sci. Reports. 99: 2571-2576.
5. Yancey, P. G., A. E. Bortnick, G. Kellner-Weibel, M. de la Llera-Moya, M. C. Phillips, and G. H. Rothblat. 2003. Importance of different pathways of cellular cholesterol efflux. Arterioscler. Thromb. Vasc. Biol. 23: In press.
6. Bortnick, A. E., G. H. Rothblat, G. Stoudt, K. L. Hoppe, L. Royer, J. McNeish, and O. L. Francone. 2000. The correlation of ATP-binding cassette 1 mRNA levels with cholesterol efflux from various cell lines. J. Biol. Chem. 275: 28634-28640.
7. Smith, J. D., M. Miyata, M. Ginsberg, C. Grigaux, E. Shmookler, and A. S. Plump. 1996. Cyclic AMP induces apolipoprotein E binding activity and promotes cholesterol efflux from a macrophage cell line to apolipoprotein acceptors. J. Biol. Chem. 271: 30647-30655.
8. Boisvert, W. A., A. S. Black, and L. K. Curtiss. 1999. ApoA1 reduces free cholesterol accumulation in atherosclerotic lesions of ApoE-deficient mice transplanted with ApoE-expressing macrophages. Arterioscler. Thromb. Vasc. Biol. 19: 525-530.
9. Langer, C., Y. Huang, P. Cullen, B. Wiesenhutter, R. W. Mahley, G. Assmann, and A. von Eckardstein. 2000. Endogenous apolipoprotein E modulates cholesterol efflux and cholesteryl ester hydrolysis mediated by high-density lipoprotein-3 and lipid-free apolipoproteins in mouse peritoneal macrophages. J. Mol. Med. 78: 217-227.
10. Mazzone, T., and C. Reardon. 1994. Expression of heterologous human apolipoprotein E by J774 macrophages enhances cholesterol efflux to HDL3. J. Lipid Res. 35: 1345-1353.
11. Lin, C. Y., M. Lucas, and T. Mazzone. 1998. Endogenous apoE expression modulates HDL3 binding to macrophages. J. Lipid Res. 39: 293-301.
12. Lin, C. Y., Z. H. Huang, and T. Mazzone. 2001. Interaction with proteoglycans enhances the sterol efflux produced by endogenous expression of macrophage apoE. J. Lipid Res. 42: 1125-1133.
13. Olin-Lewis, K., J. L. Benton, J. C. Rutledge, D. G. Baskin, T. N. Wight, and A. Chait. 2002. Apolipoprotein E mediates the retention of high-density lipoproteins by mouse carotid arteries and cultured arterial smooth muscle cell extracellular matrices. Circ. Res. 90: 1333-1339.
14. Olin, K. L., S. Potter-Perigo, P. H. Barrett, T. N. Wight, and A. Chait. 2001. Biglycan, a vascular proteoglycan, binds differently to HDL2 and HDL3: role of apoE. Arterioscler. Thromb. Vasc. Biol. 21: 129-135.
15. Williamson, R., D. Lee, J. Hagaman, and N. Maeda. 1992. Marked reduction of high density lipoprotein cholesterol in mice genetically modified to lack apolipoprotein A-I. Proc. Natl. Acad. Sci. USA. 89: 7134-7138.
16. Rudel, L. L., K. Kelley, J. K. Sawyer, R. Shah, and M. D. Wilson. 1998. Dietary monounsaturated fatty acids promote aortic atherosclerosis in LDL receptor-null, human ApoB100-overexpressing transgenic mice. Arterioscler. Thromb. Vasc. Biol. 18: 1818-1827.
17. Arbogast, L. Y., G. H. Rothblat, M. H. Leslie, and R. A. Cooper. 1976. Cellular cholesterol ester accumulation induced by free cholesterol-rich lipid dispersions. Proc Natl. Acad. Sci., USA. 73: 3680-3684.
18. Warner, G. J., G. Stoudt, M. Bamberger, W. J. Johnson, and G. H. Rothblat. 1995. Cell toxicity induced by inhibition of acyl coenzyme A cholesterol acyltransferase and accumulation of unesterified cholesterol. J. Biol. Chem. 270: 5772-5778.
19. Markwell, M. A., S. M. Hass, L. L. Bieber, and N. E. Tolbert. 1978. A modification of the Lowry procedure to simiplify protein determination in membrane and lipoprotein samples. Anal. Biochem. 87: 206-210.
20. Plump, A. S., J. D. Smith, T. Hayek, K. Aalto-Setala, A. Walsh, J. G. Verstuyft, E. M. Rubin, and J. L. Breslow. 1992. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell. 71: 343-353.
21. Arakawa, R., and S. Yokoyama. 2002. Helical apolipoproteins stabilize ATP-binding cassette transporter Al by protecting it from thiol protease-mediated degradation. J. Biol. Chem. 277: 22426-22429.
22. Oram, J. F. 2002. ATP-binding cassette transporter Al and cholesterol trafficking. Curr. Opin. Lipidol. 13: 373-381.
23. Tall, A. R., P. Costet, and N. Wang. 2002. Regulation and mechanisms of macrophage cholesterol efflux. [Review] [49 refs] J. Clin. Invest. 110: 899-904.
24. Nofer, J. R., B. Kehrel, M. Fobker, B. Levkau, G. Assmann, and A. von Eckardstein. 2002. HDL and arteriosclerosis: beyond reverse cholesterol transport. Atherosclerosis. 161: 1-16.
25. Shah, P. K., S. Kaul, J. Nilsson, and B. Cercek. 2001. Exploiting the vascular protective effects of high-density lipoprotein and its apolipoproteins: an idea whose time for testing is coming, part I. Circulation. 104: 2376-2383.
26. Yuhanna, I. S., Y. Zhu, B. E. Cox, L. D. Hahner, S. Osborne-Lawrence, P. Lu, Y. L. Marcel, R. G. Anderson, M. E. Mendelsohn, H. H. Hobbs, and P. W. Shaul. 2001. High-density lipoprotein binding to scavenger receptor-BI activates endothelial nitric oxide synthase. Nat. Med. 7: 853-857.
27. Shimano, H., J. Ohsuga, M. Shimada, Y. Namba, T. Gotoda, K. Harada, M. Katsuki, Y. Yazaki, and N. Yamada. 1995. Inhibition of diet-induced atheroma formation in transgenic mice expressing apolipoprotein E in the arterial wall. J. Clin. Invest. 95: 469-476.
28. Dyer, C. A., and L. K. Curtiss. 1988. Apoprotein E-rich high density lipoprotein inhibit ovarian androgen synthesis. J. Biol. Chem. 263: 10965-10973.
29. Reyland, M. E., J. T. Gwynne, P. Forgez, M. M. Prack, and D. L. Williams. 1991. Expression of the human apoE gene suppresses steroidogenesis in mouse Y1 adrenal cells. Proc. Natl. Acad. Sci. USA. 88: 2375-2379.
30. Riddell, D. R., A. Graham, and J. S. Owen. 1997. Apolipoprotein E inhibits platelet aggregation through the L-arginine: nitric oxide pathway. Implications for vascular disease. J. Biol. Chem. 272: 89-95.
31. Pepe, M. G., and L. K. Curtiss. 1986, Apoliprotein E is a biologically active contituent of the normal immunoregularity lipoprotein, LDL-In. J. Immunol. 136: 3716-3723.
32. Ishigami, M., D. K. Swertfeger, N. A. Granholm, and D. Y. Hui. 1998. Apolipoprotein E inhibits platelet-derived growth factor-induced vascular smooth muscle cell migration and proliferation by suppressing signal transduction and preventing cell entry to G1 phase. J. Biol. Chem. 273: 20156-20161.
33. Herz, J., and H. H. Bock. 2002. Lipoprotein receptors in the nervous system. Annu. Rev. Biochem. 71: 405-434.
34. Barnes, H., B. Larsen, M. Tyers, and G. van Der Geer. 2001. Tyrosine-phosphorylated low density lipoprotein receptor-related protein 1 (Lrp1) associates with the adaptor protein SHC in SRC-transformed cells. J. Biol. Chem. 276: 19119-19125.
35. Boucher, P., P. Liu, M. Gotthardt, T. Hiesberger, R. G. Anderson, and J. Herz. 2002. Platelet-derived growth factor mediates tyrosine phosphorylation of the cytoplasmic domain of the low density lipoprotein receptor-related protein in caveolae. J. Biol. Chem. 277: 15507-15513.
36. Loukinova, E., S. Ranganathan, S. Kuznetsov, N. Gorlatova, M. M. Migliorini, D. Loukinov, P. G. Ulery, I. Mikhailenko, D. A. Lawrence, and D. K. Strickland. 2002. Platelet-derived growth factor (PDGF)-induced tyrosine phosphorylation of the low density lipoprotein receptor-related protein (LRP). Evidence for integrated co-receptor function betwenn LRP and the PDGF. J. Biol. Chem. 277: 15499-15506.
37. Swertfeger, D. K., G. Bu, and D. Y. Hui. 2002. Low density lipoprotein receptor-related protein mediates apolipoprotein E inhibition of smooth muscle cell migration. J. Biol. Chem. 277: 4141-4146.
38. Boucher, P., M. Gotthardt, L. Li, R. G. W. Anderson, and J. Herz. 2003. LRP: role in vascular wall integrity and protection from atherosclerosis. Science. 300: 329-332.
39. Dansky, H. M., S. A. Charlton, J. L. Sikes, S. C. Heath, R. Simantov, L. F. Levin, P. Shu, K. J. Moore, J. L. Breslow, and J. D. Smith. 1999. Genetic background determines the extent of atherosclerosis in ApoE-deficient mice. Arterioscler. Thromb. Vasc. Biol. 19: 1960-1968.
40. Fournier, N., V. Atger, J. L. Paul, M. Sturm, N. Duverger, G. H. Rothblat, and N. Moatti. 2000. Human ApoA-IV overexpression in transgenic mice induces cAMP-stimulated cholesterol efflux from J774 macrophages to whole serum. Arterioscler. Thromb. Vasc. Biol. 20: 1283-1292.
41. Cohen, R. D., L. W. Castellani, J. H. Qiao, B. J. Van Lenten, A. J. Lusis, and K. Reue. 1997. Reduced aortic lesions and elevated high density lipoprotein levels in transgenic mice overexpressing mouse apolipoprotein A-IV. J. Clin. Invest. 99: 1906-1916.
42. Duverger, N., G. Tremp, J. M. Caillaud, F. Emmanuel, G. Castro, J. C. Fruchart, A. Steinmetz, and P. Denefle. 1996. Protection against atherogenesis in mice mediated by human apolipoprotein A-IV. Science. 273: 966-968.
43. Weinberg, R. B., and M. S. Spector. 1985. Structural properties and lipid binding of human apolipoprotein A-IV. J. Biol. Chem. 260: 4914-4921.
44. Sloop, C. H., L. Dory, R. Hamilton, B. R. Krause, and P. S. Roheim. 1983. Characterization of dog peripheral lymph lipoproteins: the presence of a disc-shaped "nascent" high density lipoprotein. J. Lipid Res. 24: 1429-1440.
45. Sloop, C. H., L. Dory, B. R. Krause, C. Castle, and P. S. Roheim. 1983. Lipoproteins and apolipoproteins in peripheral lymph of normal and cholesterol-fed dogs. Atherosclerosis. 49: 9-21.
46. Sloop, C. H., L. Dou, and P. S. Roheim. 1987. Interstitial fluid lipoproteins. J. Lipid Res. 28: 225-237.